The Fundamental Role of Medical Treatment in the Prevention of CarotidRelated Strokes: Insights from a Multispecialty Consensus Document
Curr Vasc Pharmacol. 2023 Nov 1. doi: 10.2174/0115701611282696231101072656. Online ahead of print.NO ABSTRACTPMID:37909660 | DOI:10.2174/0115701611282696231101072656 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - November 1, 2023 Category: Drugs & Pharmacology Authors: Kosmas I Paraskevas Piotr Musialek Dimitri P Mikhailidis Gregory Y H Lip Source Type: research
The Fundamental Role of Medical Treatment in the Prevention of CarotidRelated Strokes: Insights from a Multispecialty Consensus Document
Curr Vasc Pharmacol. 2023 Nov 1. doi: 10.2174/0115701611282696231101072656. Online ahead of print.NO ABSTRACTPMID:37909660 | DOI:10.2174/0115701611282696231101072656 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - November 1, 2023 Category: Drugs & Pharmacology Authors: Kosmas I Paraskevas Piotr Musialek Dimitri P Mikhailidis Gregory Y H Lip Source Type: research
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention
CONCLUSION: The administration of tirofiban before reperfusion therapy compared with after reperfusion therapy is more effective in reducing the hyperthrombotic load, thrombus aspiration, inflammatory factors, and cTNI and can effectively improve myocardial perfusion and heart function.PMID:37855337 | DOI:10.2174/0115701611251882231012080210 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 19, 2023 Category: Drugs & Pharmacology Authors: Xiuying Tang Runjun Li Source Type: research
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention
CONCLUSION: The administration of tirofiban before reperfusion therapy compared with after reperfusion therapy is more effective in reducing the hyperthrombotic load, thrombus aspiration, inflammatory factors, and cTNI and can effectively improve myocardial perfusion and heart function.PMID:37855337 | DOI:10.2174/0115701611251882231012080210 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 19, 2023 Category: Drugs & Pharmacology Authors: Xiuying Tang Runjun Li Source Type: research
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention
CONCLUSION: The administration of tirofiban before reperfusion therapy compared with after reperfusion therapy is more effective in reducing the hyperthrombotic load, thrombus aspiration, inflammatory factors, and cTNI and can effectively improve myocardial perfusion and heart function.PMID:37855337 | DOI:10.2174/0115701611251882231012080210 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 19, 2023 Category: Drugs & Pharmacology Authors: Xiuying Tang Runjun Li Source Type: research
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention
CONCLUSION: The administration of tirofiban before reperfusion therapy compared with after reperfusion therapy is more effective in reducing the hyperthrombotic load, thrombus aspiration, inflammatory factors, and cTNI and can effectively improve myocardial perfusion and heart function.PMID:37855337 | DOI:10.2174/0115701611251882231012080210 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 19, 2023 Category: Drugs & Pharmacology Authors: Xiuying Tang Runjun Li Source Type: research
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention
CONCLUSION: The administration of tirofiban before reperfusion therapy compared with after reperfusion therapy is more effective in reducing the hyperthrombotic load, thrombus aspiration, inflammatory factors, and cTNI and can effectively improve myocardial perfusion and heart function.PMID:37855337 | DOI:10.2174/0115701611251882231012080210 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 19, 2023 Category: Drugs & Pharmacology Authors: Xiuying Tang Runjun Li Source Type: research
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention
CONCLUSION: The administration of tirofiban before reperfusion therapy compared with after reperfusion therapy is more effective in reducing the hyperthrombotic load, thrombus aspiration, inflammatory factors, and cTNI and can effectively improve myocardial perfusion and heart function.PMID:37855337 | DOI:10.2174/0115701611251882231012080210 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 19, 2023 Category: Drugs & Pharmacology Authors: Xiuying Tang Runjun Li Source Type: research
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention
CONCLUSION: The administration of tirofiban before reperfusion therapy compared with after reperfusion therapy is more effective in reducing the hyperthrombotic load, thrombus aspiration, inflammatory factors, and cTNI and can effectively improve myocardial perfusion and heart function.PMID:37855337 | DOI:10.2174/0115701611251882231012080210 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 19, 2023 Category: Drugs & Pharmacology Authors: Xiuying Tang Runjun Li Source Type: research
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention
CONCLUSION: The administration of tirofiban before reperfusion therapy compared with after reperfusion therapy is more effective in reducing the hyperthrombotic load, thrombus aspiration, inflammatory factors, and cTNI and can effectively improve myocardial perfusion and heart function.PMID:37855337 | DOI:10.2174/0115701611251882231012080210 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 19, 2023 Category: Drugs & Pharmacology Authors: Xiuying Tang Runjun Li Source Type: research
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention
CONCLUSION: The administration of tirofiban before reperfusion therapy compared with after reperfusion therapy is more effective in reducing the hyperthrombotic load, thrombus aspiration, inflammatory factors, and cTNI and can effectively improve myocardial perfusion and heart function.PMID:37855337 | DOI:10.2174/0115701611251882231012080210 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 19, 2023 Category: Drugs & Pharmacology Authors: Xiuying Tang Runjun Li Source Type: research
Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention
CONCLUSION: The administration of tirofiban before reperfusion therapy compared with after reperfusion therapy is more effective in reducing the hyperthrombotic load, thrombus aspiration, inflammatory factors, and cTNI and can effectively improve myocardial perfusion and heart function.PMID:37855337 | DOI:10.2174/0115701611251882231012080210 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 19, 2023 Category: Drugs & Pharmacology Authors: Xiuying Tang Runjun Li Source Type: research
The Effect of Menopause and Menopausal Hormone Therapy on the Risk of Peripheral Artery Disease
Curr Vasc Pharmacol. 2023 Sep 27. doi: 10.2174/0115701611263345230919122907. Online ahead of print.ABSTRACTPeripheral artery disease (PAD), defined as lower extremity arterial disease, constitutes an underestimated aspect of the menopause-associated risk of atherosclerotic cardiovascular disease (ASCVD). Accumulation of ASCVD risk factors, such as atherogenic dyslipidaemia, diabetes, and arterial hypertension, after the transition to menopause may contribute to atherosclerotic plaque formation in peripheral arteries. However, inconsistency exists among studies as to whether transition to menopause increases the risk of PAD...
Source: Current Vascular Pharmacology - October 2, 2023 Category: Drugs & Pharmacology Authors: Panagiotis Anagnostis Dimitri P Mikhailidis Ales Blinc Mojca Jensterle Mateja K Je žovnik Gerit-Holger Schernthaner Pier Luigi Antignani Katica Bajuk Studen Miso Šabović Pavel Poredos Source Type: research
Cardiometabolic Risk, Peripheral Arterial Disease and Cardiovascular Events in Polycystic Ovary Syndrome: Time to Implement Systematic Screening and Update the Management
Curr Vasc Pharmacol. 2023 Sep 27. doi: 10.2174/0115701611269146230920073301. Online ahead of print.ABSTRACTPolycystic ovary syndrome (PCOS) is a highly prevalent endocrine disorder in women of reproductive age. It presents with gynaecologic, metabolic, and psychologic manifestations. The dominant drivers of pathophysiology are hyperandrogenism and insulin resistance. Both conditions are related to cardiometabolic risk factors, such as obesity, hypertension, dyslipidaemia, hyperglycaemia, type 2 and gestational diabetes, nonalcoholic fatty liver disease and obstructive sleep apnoea. Women with PCOS of reproductive age consi...
Source: Current Vascular Pharmacology - October 2, 2023 Category: Drugs & Pharmacology Authors: Andrej Janez Rok Herman Pavel Poredos Dimitri P Mikhailidis Ales Blinc Miso Sabovic Katica Bajuk Studen Mateja Kaja Jezovnik Gerit-Holger Schernthaner Panagiotis Anagnostis Pier Luigi Antignani Mojca Jensterle Source Type: research
Analysis of the Research Hotspot of Exosomes in Cardiovascular Disease: A Bibliometric-based Literature Review
CONCLUSION: Research on exosomes in CVD has attracted considerable attention, with China having the most published studies. Fundamental research has focused on CVD pathogenesis; exosomes regulate the progression of CVD through biological processes, such as the inflammatory response, autophagy, and apoptosis. Clinical research has focused on biomarkers for CVD; studies on using miRNAs in exosomes as disease markers for diagnosis could become a future trend.PMID:37779407 | DOI:10.2174/0115701611249727230920042944 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 2, 2023 Category: Drugs & Pharmacology Authors: Jing Cui Yiwen Li Mengmeng Zhu Yanfei Liu Yue Liu Source Type: research
